TISIDB

Summary
Symbol	CAMK2B
Name	calcium/calmodulin-dependent protein kinase II beta
Aliases	CAM2; CAMK2; CaM-kinase II beta chain; calcium/calmodulin-dependent protein kinase type II beta chain; CaM k ......
Chromosomal Location	7p14.3-p14.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm, cytoskeleton Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Sarcoplasmic reticulum membrane Peripheral membrane protein Cytoplasmic side Cell junction, synapse Note=In slow-twitch muscle, evenly distributed between longitudinal SR and junctional SR.
Domain	PF08332 Calcium/calmodulin dependent protein kinase II association domain PF00069 Protein kinase domain
Function	Calcium/calmodulin-dependent protein kinase that functions autonomously after Ca(2+)/calmodulin-binding and autophosphorylation, and is involved in dendritic spine and synapse formation, neuronal plasticity and regulation of sarcoplasmic reticulum Ca(2+) transport in skeletal muscle. In neurons, plays an essential structural role in the reorganization of the actin cytoskeleton during plasticity by binding and bundling actin filaments in a kinase-independent manner. This structural function is required for correct targeting of CaMK2A, which acts downstream of NMDAR to promote dendritic spine and synapse formation and maintain synaptic plasticity which enables long-term potentiation (LTP) and hippocampus-dependent learning. In developing hippocampal neurons, promotes arborization of the dendritic tree and in mature neurons, promotes dendritic remodeling. Participates in the modulation of skeletal muscle function in response to exercise. In slow-twitch muscles, is involved in regulation of sarcoplasmic reticulum (SR) Ca(2+) transport and in fast-twitch muscle participates in the control of Ca(2+) release from the SR through phosphorylation of triadin, a ryanodine receptor-coupling factor, and phospholamban (PLN/PLB), an endogenous inhibitor of SERCA2A/ATP2A2.

> Gene Ontology [ TOP ]
Biological Process	GO:0003012 muscle system process GO:0006816 calcium ion transport GO:0009266 response to temperature stimulus GO:0009408 response to heat GO:0010720 positive regulation of cell development GO:0010769 regulation of cell morphogenesis involved in differentiation GO:0010770 positive regulation of cell morphogenesis involved in differentiation GO:0010959 regulation of metal ion transport GO:0010975 regulation of neuron projection development GO:0010976 positive regulation of neuron projection development GO:0014733 regulation of skeletal muscle adaptation GO:0014888 striated muscle adaptation GO:0016358 dendrite development GO:0021700 developmental maturation GO:0022604 regulation of cell morphogenesis GO:0031346 positive regulation of cell projection organization GO:0034341 response to interferon-gamma GO:0034605 cellular response to heat GO:0043500 muscle adaptation GO:0043501 skeletal muscle adaptation GO:0043502 regulation of muscle adaptation GO:0044057 regulation of system process GO:0045666 positive regulation of neuron differentiation GO:0046777 protein autophosphorylation GO:0048167 regulation of synaptic plasticity GO:0048168 regulation of neuronal synaptic plasticity GO:0048169 regulation of long-term neuronal synaptic plasticity GO:0048667 cell morphogenesis involved in neuron differentiation GO:0048813 dendrite morphogenesis GO:0048814 regulation of dendrite morphogenesis GO:0050769 positive regulation of neurogenesis GO:0050773 regulation of dendrite development GO:0050775 positive regulation of dendrite morphogenesis GO:0050803 regulation of synapse structure or activity GO:0050804 modulation of synaptic transmission GO:0050807 regulation of synapse organization GO:0050808 synapse organization GO:0051823 regulation of synapse structural plasticity GO:0051924 regulation of calcium ion transport GO:0051962 positive regulation of nervous system development GO:0060074 synapse maturation GO:0060333 interferon-gamma-mediated signaling pathway GO:0060996 dendritic spine development GO:0060997 dendritic spine morphogenesis GO:0060998 regulation of dendritic spine development GO:0060999 positive regulation of dendritic spine development GO:0061001 regulation of dendritic spine morphogenesis GO:0061003 positive regulation of dendritic spine morphogenesis GO:0070838 divalent metal ion transport GO:0071346 cellular response to interferon-gamma GO:0072511 divalent inorganic cation transport GO:0090128 regulation of synapse maturation GO:0090129 positive regulation of synapse maturation GO:0090257 regulation of muscle system process GO:0097061 dendritic spine organization GO:1900006 positive regulation of dendrite development GO:1900034 regulation of cellular response to heat
Molecular Function	GO:0003779 actin binding GO:0004674 protein serine/threonine kinase activity GO:0004683 calmodulin-dependent protein kinase activity GO:0005085 guanyl-nucleotide exchange factor activity GO:0005088 Ras guanyl-nucleotide exchange factor activity GO:0005516 calmodulin binding
Cellular Component	GO:0016528 sarcoplasm GO:0016529 sarcoplasmic reticulum GO:0030139 endocytic vesicle GO:0030659 cytoplasmic vesicle membrane GO:0030666 endocytic vesicle membrane GO:0033017 sarcoplasmic reticulum membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04012 ErbB signaling pathway hsa04020 Calcium signaling pathway hsa04024 cAMP signaling pathway hsa04066 HIF-1 signaling pathway hsa04114 Oocyte meiosis hsa04261 Adrenergic signaling in cardiomyocytes hsa04310 Wnt signaling pathway hsa04360 Axon guidance hsa04713 Circadian entrainment hsa04720 Long-term potentiation hsa04722 Neurotrophin signaling pathway hsa04725 Cholinergic synapse hsa04728 Dopaminergic synapse hsa04740 Olfactory transduction hsa04750 Inflammatory mediator regulation of TRP channels hsa04911 Insulin secretion hsa04912 GnRH signaling pathway hsa04916 Melanogenesis hsa04921 Oxytocin signaling pathway hsa04922 Glucagon signaling pathway hsa04971 Gastric acid secretion
Reactome	R-HSA-170984: ARMS-mediated activation R-HSA-442755: Activation of NMDA receptor upon glutamate binding and postsynaptic events R-HSA-422475: Axon guidance R-HSA-442729: CREB phosphorylation through the activation of CaMKII R-HSA-442742: CREB phosphorylation through the activation of Ras R-HSA-5576891: Cardiac conduction R-HSA-3371556: Cellular response to heat stress R-HSA-2262752: Cellular responses to stress R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-2172127: DAP12 interactions R-HSA-2424491: DAP12 signaling R-HSA-1266738: Developmental Biology R-HSA-186763: Downstream signal transduction R-HSA-2871796: FCERI mediated MAPK activation R-HSA-2454202: Fc epsilon receptor (FCERI) signaling R-HSA-170968: Frs2-mediated activation R-HSA-179812: GRB2 events in EGFR signaling R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK R-HSA-399721: Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity R-HSA-3371571: HSF1-dependent transactivation R-HSA-2428924: IGF1R signaling cascade R-HSA-112399: IRS-mediated signalling R-HSA-2428928: IRS-related events triggered by IGF1R R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-74751: Insulin receptor signalling cascade R-HSA-913531: Interferon Signaling R-HSA-877300: Interferon gamma signaling R-HSA-912526: Interleukin receptor SHC signaling R-HSA-451927: Interleukin-2 signaling R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling R-HSA-983712: Ion channel transport R-HSA-5578775: Ion homeostasis R-HSA-936837: Ion transport by P-type ATPases R-HSA-5683057: MAPK family signaling cascades R-HSA-5684996: MAPK1/MAPK3 signaling R-HSA-397014: Muscle contraction R-HSA-375165: NCAM signaling for neurite out-growth R-HSA-187037: NGF signalling via TRKA from the plasma membrane R-HSA-112316: Neuronal System R-HSA-112314: Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell R-HSA-5576892: Phase 0 - rapid depolarisation R-HSA-438064: Post NMDA receptor activation events R-HSA-169893: Prolonged ERK activation events R-HSA-5673001: RAF/MAP kinase cascade R-HSA-8853659: RET signaling R-HSA-442982: Ras activation uopn Ca2+ infux through NMDA receptor R-HSA-180336: SHC1 events in EGFR signaling R-HSA-112412: SOS-mediated signalling R-HSA-162582: Signal Transduction R-HSA-177929: Signaling by EGFR R-HSA-372790: Signaling by GPCR R-HSA-74752: Signaling by Insulin receptor R-HSA-449147: Signaling by Interleukins R-HSA-2586552: Signaling by Leptin R-HSA-186797: Signaling by PDGF R-HSA-1433557: Signaling by SCF-KIT R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) R-HSA-194138: Signaling by VEGF R-HSA-166520: Signalling by NGF R-HSA-187687: Signalling to ERKs R-HSA-167044: Signalling to RAS R-HSA-187706: Signalling to p38 via RIT and RIN R-HSA-399719: Trafficking of AMPA receptors R-HSA-382551: Transmembrane transport of small molecules R-HSA-112315: Transmission across Chemical Synapses R-HSA-438066: Unblocking of NMDA receptor, glutamate binding and activation R-HSA-4420097: VEGFA-VEGFR2 Pathway R-HSA-5218921: VEGFR2 mediated cell proliferation

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04012 ErbB signaling pathway
hsa04020 Calcium signaling pathway
hsa04024 cAMP signaling pathway
hsa04066 HIF-1 signaling pathway
hsa04114 Oocyte meiosis
hsa04261 Adrenergic signaling in cardiomyocytes
hsa04310 Wnt signaling pathway
hsa04360 Axon guidance
hsa04713 Circadian entrainment
hsa04720 Long-term potentiation
hsa04722 Neurotrophin signaling pathway
hsa04725 Cholinergic synapse
hsa04728 Dopaminergic synapse
hsa04740 Olfactory transduction
hsa04750 Inflammatory mediator regulation of TRP channels
hsa04911 Insulin secretion
hsa04912 GnRH signaling pathway
hsa04916 Melanogenesis
hsa04921 Oxytocin signaling pathway
hsa04922 Glucagon signaling pathway
hsa04971 Gastric acid secretion

Reactome

R-HSA-170984: ARMS-mediated activation
R-HSA-442755: Activation of NMDA receptor upon glutamate binding and postsynaptic events
R-HSA-422475: Axon guidance
R-HSA-442729: CREB phosphorylation through the activation of CaMKII
R-HSA-442742: CREB phosphorylation through the activation of Ras
R-HSA-5576891: Cardiac conduction
R-HSA-3371556: Cellular response to heat stress
R-HSA-2262752: Cellular responses to stress
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-186763: Downstream signal transduction
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-399721: Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity
R-HSA-3371571: HSF1-dependent transactivation
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-913531: Interferon Signaling
R-HSA-877300: Interferon gamma signaling
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-983712: Ion channel transport
R-HSA-5578775: Ion homeostasis
R-HSA-936837: Ion transport by P-type ATPases
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-397014: Muscle contraction
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-112316: Neuronal System
R-HSA-112314: Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
R-HSA-5576892: Phase 0 - rapid depolarisation
R-HSA-438064: Post NMDA receptor activation events
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-442982: Ras activation uopn Ca2+ infux through NMDA receptor
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-399719: Trafficking of AMPA receptors
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-112315: Transmission across Chemical Synapses
R-HSA-438066: Unblocking of NMDA receptor, glutamate binding and activation
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation

Summary
Symbol	CAMK2B
Name	calcium/calmodulin-dependent protein kinase II beta
Aliases	CAM2; CAMK2; CaM-kinase II beta chain; calcium/calmodulin-dependent protein kinase type II beta chain; CaM k ......
Chromosomal Location	7p14.3-p14.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CAMK2B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	CAMK2B
Name	calcium/calmodulin-dependent protein kinase II beta
Aliases	CAM2; CAMK2; CaM-kinase II beta chain; calcium/calmodulin-dependent protein kinase type II beta chain; CaM k ......
Chromosomal Location	7p14.3-p14.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CAMK2B in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CAMK2B
Name	calcium/calmodulin-dependent protein kinase II beta
Aliases	CAM2; CAMK2; CaM-kinase II beta chain; calcium/calmodulin-dependent protein kinase type II beta chain; CaM k ......
Chromosomal Location	7p14.3-p14.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CAMK2B in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.105	0.668
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.178	0.682
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.317	0.41
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.203	0.672
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.124	0.911
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.616	0.639
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.269	0.693
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.343	0.737
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.872	0.436
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.45	0.429
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.66	0.39
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.67	0.0169

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CAMK2B in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	5.9	-5.9	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	7.1	-7.1	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	2.7	1	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.4	0.3	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	5.9	-1.1	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CAMK2B
Name	calcium/calmodulin-dependent protein kinase II beta
Aliases	CAM2; CAMK2; CaM-kinase II beta chain; calcium/calmodulin-dependent protein kinase type II beta chain; CaM k ......
Chromosomal Location	7p14.3-p14.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CAMK2B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CAMK2B
Name	calcium/calmodulin-dependent protein kinase II beta
Aliases	CAM2; CAMK2; CaM-kinase II beta chain; calcium/calmodulin-dependent protein kinase type II beta chain; CaM k ......
Chromosomal Location	7p14.3-p14.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CAMK2B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CAMK2B. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CAMK2B
Name	calcium/calmodulin-dependent protein kinase II beta
Aliases	CAM2; CAMK2; CaM-kinase II beta chain; calcium/calmodulin-dependent protein kinase type II beta chain; CaM k ......
Chromosomal Location	7p14.3-p14.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CAMK2B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CAMK2B
Name	calcium/calmodulin-dependent protein kinase II beta
Aliases	CAM2; CAMK2; CaM-kinase II beta chain; calcium/calmodulin-dependent protein kinase type II beta chain; CaM k ......
Chromosomal Location	7p14.3-p14.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CAMK2B expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CAMK2B
Name	calcium/calmodulin-dependent protein kinase II beta
Aliases	CAM2; CAMK2; CaM-kinase II beta chain; calcium/calmodulin-dependent protein kinase type II beta chain; CaM k ......
Chromosomal Location	7p14.3-p14.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CAMK2B and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CAMK2B
Name	calcium/calmodulin-dependent protein kinase II beta
Aliases	CAM2; CAMK2; CaM-kinase II beta chain; calcium/calmodulin-dependent protein kinase type II beta chain; CaM k ......
Chromosomal Location	7p14.3-p14.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CAMK2B collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting CAMK2B.

ID	Name	Drug Type	Targets	#Targets
DB07168	[4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-(methylamino)pyrimidin-2-yl}amino)phenyl]acetonitrile	Small Molecule	CAMK2B	1

Browse CAMK2B